Pasithea Therapeutics Corp
pasithea.comWhat Do They Do?
Develops drug candidates for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system disorders.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$5.3MView ↗
- ▲ +42% (Loss)
- vs −$3.7M in Q2 FY2025
-
Aug 21, 2026
Nasdaq extended the deadline to regain the minimum bid price requirement
The company has until February 16, 2027, to regain compliance or its common stock may be subject to delisting.
Sources
8-K, filed Aug 21, 2026
On August 20, 2026, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to February…View ↗
Clinics segment
The older report described business-support services for anti-depression clinics alongside drug research. The latest report describes primary operations as drug development and says clinic operations have been discontinued.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 30, 2026
Who Do They Compete With?
Competes with GSK, Novartis, Pfizer, Genentech, Verastem, AstraZeneca, Merck &, SpringWorks Therapeutics, Array BioPharma, Chia Tai Tianqing Pharmaceutical Group, Healx, Infixion Bioscience, Novartis International, Shanghai Fosun Pharmaceutical (Group), Shanghai Kechow Pharma, and NFlection Therapeutics
10-K for FY2025, filed Mar 30, 2026Companies with FDA approved MEK inhibitors include: GSK plc, which received FDA approval for Mekinist (trametinib), that was subsequently…View ↗
Loading...
